Skip to main content Skip to main navigation menu Skip to site footer

Infeksi COVID-19 pada pasien myasthenia gravis: sebuah tinjauan pustaka



Abstract

Coronavirus disease (COVID-19) has rapidly become a global pandemic and during this condition, there might be at greater risk of exacerbation in patients with myasthenia gravis. This is related to the viral infection that has been known to increase the risk of a myasthenic crisis. In addition, some experimental drugs used in COVID-19 has been reported to increase the risk of exacerbation in patient with myasthenia gravis. In the other hand, several studies show higher morbidity and mortality rates due to COVID-19 in patient with myasthenia gravis. Myasthenia gravis might be a risk factor for severe COVID-19 infection due to several mechanisms, such as the effect of the immunosuppressive therapy and the inherent respiratory muscle weakness and vulnerabilities. The comprehensive study based on several case report is needed to respond the needs of adaptation in treating patient with myasthenia gravis during this pandemic era.

 

 

Coronavirus disease (COVID-19) telah menjadi pandemi global dalam waktu singkat. Selama pandemi ini, terdapat peningkatan resiko eksaserbasi pada pasien dengan myasthenia gravis. Hal ini terjadi karena sejak lama telah diketahui bahwa infeksi virus dapat meningkatkan resiko krisis myasthenia pada pasien myasthenia gravis. Beberapa obat eksperimental yang diberikan pada pasien dengan infeksi COVID-19 juga dilaporkan memiliki resiko yang tinggi dalam menimbulkan eksaserbasi gejala myasthenia gravis. Di sisi lain, beberapa studi terkait COVID-19 menunjukkan angka morbiditas dan mortalitas yang lebih tinggi pada pasien dengan myasthenia gravis. Myasthenia gravis juga merupakan faktor resiko untuk infeksi COVID-19 berat yang berhubungan degan beberapa mekanisme seperti efek dari terapi imunosupresan dan kondisi kelemahan otot pernafasan pada penyakit myasthenia gravis. Telaah yang komprehensif berdasarkan beberapa laporan kasus terkait infeksi COVID-19 pada pasien myasthenia gravis sangat diperlukan untuk melakukan adaptasi manajemen terapi pada era pandemi ini.

Keywords: COVID-19 myasthenia gravis infeksi resiko eksaserbasi

References

  1. WHO. Coronavirus disease (COVID-19) situation reports [Internet]. World Health Organisation. 2020. p. 1. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
  2. Muppidi S, Guptill JT, Jacob S, Li Y, Farrugia ME, Guidon AC, et al. COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurol. 2020;19(12):970–1. Available from: https://pubmed.ncbi.nlm.nih.gov/33212055
  3. Aksoy E, Oztutgan T. COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature. Case Rep Infect Dis. 2020;2020:8845844. Available from: https://pubmed.ncbi.nlm.nih.gov/32850160
  4. Chairunisa N, Zanariah Z, Saputra O, Karyanto K. Myasthenia gravis pada Pasien Laki-laki 39 Tahun dengan Sesak Napas. Medula. 2016;6(1):108–14. Available from: http://juke.kedokteran.unila.ac.id/index.php/medula/article/view/858
  5. Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS, et al. Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes. Front Neurol. 2020;11:1053. Available from: https://pubmed.ncbi.nlm.nih.gov/33013676
  6. Fares E, Tayyar R, Pathak K, Damiano C, Kuntz C. Myasthenia gravis crisis triggered by covid-19. Chest. 2020;158(4):A734. Available from: http://dx.doi.org/10.1016/j.chest.2020.08.688
  7. Anand P, Slama MCC, Kaku M, Ong C, Cervantes-Arslanian AM, Zhou L, et al. COVID-19 in patients with myasthenia gravis. Muscle Nerve. 2020;62(2):254–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32392389
  8. Arie A. GAA, Adnyana MO, Widyadharma IPE. Myasthenia gravis, diagnosis and treatment. E-jurnal Med Udayana. 2013;2(6):1012–35. Available from: https://ojs.unud.ac.id/index.php/eum/article/view/5622
  9. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:874680. Available from: https://pubmed.ncbi.nlm.nih.gov/23193443
  10. Statland JM, Ciafaloni E. Myasthenia gravis: Five new things. Neurol Clin Pract. 2013;3(2):126–33. Available from: https://pubmed.ncbi.nlm.nih.gov/23914322
  11. Harkitasari S. Diagnosis dan Terapi Miastenia Gravis pada Anak. Cermin Dunia Kedokt. 2015;42(3):181–5. Available from: http://www.cdkjournal.com/index.php/CDK/article/view/1030
  12. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311–37. Available from: https://pubmed.ncbi.nlm.nih.gov/29655452
  13. Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2020;1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/33047223
  14. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020;11(7):995–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32167747
  15. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128-136.e4. Available from: https://pubmed.ncbi.nlm.nih.gov/32425269
  16. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. Lancet Neurol. 2020;19(9):767–83. Available from: https://pubmed.ncbi.nlm.nih.gov/32622375
  17. Singh S, Govindarajan R. COVID-19 and generalized Myasthenia Gravis exacerbation: A case report. Clin Neurol Neurosurg. 2020;196:106045. Available from: https://pubmed.ncbi.nlm.nih.gov/32634699
  18. Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA. 2020;323(15):1499. Available from: http://dx.doi.org/10.1001/jama.2020.3633
  19. Meng L, Qiu H, Wan L, Ai Y, Xue Z, Guo Q, et al. Intubation and Ventilation amid the COVID-19 Outbreak: Wuhan’s Experience. Anesthesiology. 2020;132(6):1317–32. Available from: https://pubmed.ncbi.nlm.nih.gov/32195705
  20. Group IM-19 W, Jacob S, Muppidi S, Guidon A, Guptill J, Hehir M, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. J Neurol Sci. 2020;412:116803. Available from: https://pubmed.ncbi.nlm.nih.gov/32247193
  21. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419–25. Available from: https://pubmed.ncbi.nlm.nih.gov/27358333
  22. Moschella P, Roth P. Isolated COVID-19 Infection Precipitates Myasthenia Gravis Crisis: A Case Report. Clin Pract cases Emerg Med. 2020;4(4):524–6. Available from: https://pubmed.ncbi.nlm.nih.gov/33217262
  23. Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol. 2018;265(6):1251–8. Available from: http://dx.doi.org/10.1007/s00415-018-8751-9
  24. Jallouli M, Saadoun D, Eymard B, Leroux G, Haroche J, Thi Huong D, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2011;259(7):1290–7. Available from: http://dx.doi.org/10.1007/s00415-011-6335-z
  25. Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord. 2017;27(6):565–8. Available from: http://dx.doi.org/10.1016/j.nmd.2017.03.007
  26. Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T, et al. Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy. JAMA Neurol. 2013;70(3):394. Available from: http://dx.doi.org/10.1001/jamaneurol.2013.1246
  27. Rein N, Haham N, Orenbuch-Harroch E, Romain M, Argov Z, Vaknin-Dembinsky A, et al. Description of 3 patients with myasthenia gravis and COVID-19. J Neurol Sci. 2020;417:117053. Available from: https://pubmed.ncbi.nlm.nih.gov/32731059
  28. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2021436

How to Cite

Setiawan, M. R. D., & Sumada, I. K. (2021). Infeksi COVID-19 pada pasien myasthenia gravis: sebuah tinjauan pustaka. Intisari Sains Medis, 12(1), 285–289. https://doi.org/10.15562/ism.v12i1.991
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
513

Total
831

Share

Search Panel

Made Ratna Dewi Setiawan
Google Scholar
Pubmed
ISM Journal

I Ketut Sumada
Google Scholar
Pubmed
ISM Journal